Effectiveness of Infliximab in Pityriasis Rubra Pilaris Is Associated with Pro-Inflammatory Cytokine Inhibition
Authors:
- L. Adnot-DesanlisLAL. Adnot-Desanlis
- F. AntonicelliFAF. Antonicelli
- T. TabaryTTT. Tabary
- P. BernardPBP. Bernard
- Z. ReguiaïZRZ. Reguiaï
- 19 March 2013
- journal article
- Published by S. Karger AG in Dermatology
- Vol. 226 (1) , 41-46
Abstract
Background: Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease. Recently, the use of anti-TNF-α in treating resistant forms of PRP has been reported. Objectives: To evaluate the clinical efficacy of infliximab in the treatment of PRP along with the evolution of secretion of some serum cytokines during treatment. Methods: Patients presenting widespread PRP were included consecutively and treated with infliximab. We compared cytokine profiles (notably CXCL-10 and TNF-α) by ELISA in sera from both patients with PRP and controls (healthy/psoriasis) at the time of diagnosis and after clinical remission (PRP). Results: 4 patients were treated with infliximab and achieved complete remission without any recurrence after treatment ending. The serum level of TNF-α and CXCL-10 was increased at the time of inclusion and normalized after treatment. Analysis of the typical component of the T helper cell 1 (Th1) and Th2 cytokine network did not show modification. Conclusion: Infliximab is an effective treatment of PRP. The analysis of the cytokine profile is in agreement with an absence of further recurrence of PRP by an early and unique inflammatory mechanism without significant underlying autoimmunity.Keywords
This publication has 25 references indexed in Scilit:
- Familial Pityriasis Rubra Pilaris Is Caused by Mutations in CARD14The American Journal of Human Genetics, 2012
- Pityriasis rubra pilaris successfully treated with adalimumabClinical and Experimental Dermatology, 2010
- Rapid and sustained remission of pityriasis rubra pilaris with adalimumab treatmentClinical and Experimental Dermatology, 2010
- Treatment of pityriasis rubra pilaris with ustekinumabBritish Journal of Dermatology, 2010
- Serum cytokines and growth factor levels in Japanese patients with psoriasisClinical and Experimental Dermatology, 2009
- PsoriasisNew England Journal of Medicine, 2009
- Treatment of juvenile pityriasis rubra pilaris with etanerceptJournal of the American Academy of Dermatology, 2008
- Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: Case report and review of the literature on biologic therapyJournal of the American Academy of Dermatology, 2008
- Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximabJournal of the European Academy of Dermatology and Venereology, 2007
- IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesisJournal of Experimental Medicine, 2006